Saprochaete capitata (S. capitata) is a very rare fungal pathogen that causes disseminated opportunistic infections in patients with hematologic malignancies. Fever resistant to broad-spectrum antibiotic and antifungal treatment is common in the presence of fungemia during the period of profound neutropenia. We describe three cases of leukemic children who died from S. capitata fungemia following a first febrile neutropenic episode after the induction of chemotherapy. S. capitata fungemia is an emergent infection associated with high mortality and low susceptibility to fluconazole and echinocandins. Awareness of this emergent infection is needed to ensure that it can be properly treated.
A AB BS S T TR RA AC CT T O Ob bj je ec ct ti iv ve e: : Wheezing is a common symptom among children and is proposed to be associated with inflammatory cell infiltration, cytokines production, and with some risk factors such as gastro esophageal reflux (GER). The aim of the present study was to investigate endotheline-1 (ET-1) and leukotriene-E4 (LTE-4) levels, their response to steroid and β2-agonist therapy, and to establish if these parameters can be used as a diagnostic tool for infantile asthma and assess their relation with GER during acute attack of wheezy infants (WI). M Ma at te er ri ia al l a an nd d M Me et th ho od ds s: : Thirty WI and 12 healthy infants were enrolled in the present study. Serum IgE, ET-1, urine LTE-4 levels, and eosinophil percentage were measured prior to and 5 days after the treatment (systemic or inhaled steroid therapy and inhaled β2-agonist) in children with WI. In addition, esophageal pH was monitored for 24 hours. R Re es su ul lt ts s: : Serum IgE, ET-1, and urine LTE-4 levels were significantly higher in the patients compared to the controls before and five days after the treatment (p= 0.009; p= 0.039, p= 0.032; p= 0.014, p= 0.017, respectively). The serum IgE and urine LTE-4 levels prior to and 5 days after the treatment were higher in the patients with GER when compared to the controls (p= 0.021, p= 0.016 and p= 0.039). Moreover, the systemic or inhaled steroid therapy did not influence the serum ET-1 and urine LT-E4 levels. We found that the serum IgE and ET-1 levels on 5 th day of the treatment and LTE-4 levels at the beginning and 5 th day of the treatment were notably different in patients with higher likelihood for developing infantile asthma when compared to the controls. Finally, increased serum IgE levels were present in patients with good response to inhaled β2-agonist with regard to those with poor response to inhaled β2-agonist (p= 0.031). C Co on nc cl lu us si io on n: : The present study indicated that IgE, ET-1 and LTE-4 levels were related to airway inflammation in WI while LTE-4 and IgE levels were associated with GER. LTE-4 and IgE levels could be novel parameters for determining the risk factor for developing asthma in child with WI. Inhaled β2-agonist therapy seemed to be beneficial only in patients with high serum IgE levels. K Ke ey y W Wo or rd ds s: : Gastroesophageal reflux; leukotriene e4; endothelin-1; asthma Ö ÖZ ZE ET T A Am ma aç ç: : Hışıltı, çocuklarda yaygın bir semptomdur ve inflamatuar hücre infiltrasyonu, sitokinler ve gastro ösefageal reflü (GER) gibi bazı risk faktörleri hışıltı gelişmesini açıklamak için önerilmiştir. Bu çalışmanın amacı, hışıltılı çocuk (HÇ) tanılı hastaların akut atakları sırasında endotelin-1 (ET-1) ve lökotrien-E4'ün (LTE-4) düzeylerini, bu düzeylerin steroid ve β2-agonist tedavisine yanıtlarını, GER ile ilişkisini ve astım gelişmesini saptamak için yeni parametreler olup olmadıklarını araştırmaktır. G Ge er re eç ç v ve e Y Yö ön nt te em ml le er r: : Yirmi HÇ ve 12 sağlıklı çocuk çalışmaya alındı. HÇ hastala...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.